-
Mashup Score: 0
During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer - 4 day(s) ago
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer - 6 day(s) ago
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3‘Patient Is Otherwise Healthy’ - 11 day(s) ago
Let me start by saying: I know I am one of the fortunate ones. Being diagnosed with cancer at any age puts many in a tailspin. I was no different when I was diagnosed with stage II testicular cancer at age 22 years. I was still in graduate school, completing my physical therapy program; suddenly, I had to schedule an orchiectomy, retroperitone al lymph node dissection, and two cycles of chemotherapy around lectures, laboratory work, and practical examinations. Fast forward 20 years and I have an unbelievab
Source: ascopubs.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
Nivolumab monotherapy and nivolumab plus ipilimumab combination therapy showed promise in the CheckMate 358 study as potential treatment options for recurrent or metastatic cervical cancer. Future randomised controlled trials of nivolumab plus ipilimumab or other dual immunotherapy regimens are warranted to confirm treatment benefit in this patient population.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Leveraging Biomarkers to Advance Endometrial Cancer Care - 27 day(s) ago
Ramez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3DUO-E Trial Data Support Durvalumab Combo as Potential Frontline Option in Advanced Endometrial Cancer - 27 day(s) ago
Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib + pembrolizumab who experienced grade 2 treatment-related hypertension. #gyncsm | @WUSTLmed https://t.co/nPKeYYYeMl